Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Corcept Therapeutics Inc maintains a gross margin of 98.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 2.22%, while the net margin is 12.02%. These profitability ratios, combined with a Return on Equity (ROE) of 15.01%, provide a clear picture of how effectively CORT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CORT competes directly with industry leaders such as ALMS and LGND. With a market capitalization of $3.83B, it holds a significant position in the sector. When comparing efficiency, CORT's gross margin of 98.74% stands against ALMS's 100.00% and LGND's 81.42%. Such benchmarking helps identify whether Corcept Therapeutics Inc is trading at a premium or discount relative to its financial performance.
